Urease-IN-24

Urease-IN-24 (AF57) (48 h) inhibits planktonic growth and cell urease activity of clinical isolates of Cryptococcus neoformans and Cryptococcus gattii in RPMI and Christensen media, with IC₅₀ values ranging from ≤0.1-6 μM, IC₉₀ values ranging from 0.3-12 μM, IC_URE values ranging from ≤0.1-1.5 μM, and MFC values ranging from 0.3-48 μM, depending on the species and medium^[1].
Urease-IN-24 inhibits biofilm formation and growth of dispersed biofilm cells of Cryptococcus neoformans H99 and Cryptococcus gattii R265 with IC₉₀ values of 3-6 μM and DMIC values of 6 μM, but does not inhibit metabolic activity of preformed mature biofilm sessile cells at concentrations up to 378 μM^[1].
Urease-IN-24 (3 μM; 48 h) significantly reduces capsule thickness of Cryptococcus neoformans H99 and Cryptococcus gattii R265^[1].
Urease-IN-24 (3-6 μM; 96 h) completely inhibits melanin production in Cryptococcus neoformans H99 and Cryptococcus gattii R265 after 96 h of incubation on L-DOPA-supplemented medium^[1].
Urease-IN-24 (3-48 μM; 0-72 h) exhibits fungicidal activity against Cryptococcus neoformans H99 and Cryptococcus gattii R265, reducing viability to undetectable levels within 12 h at 2×IC₉₀ (12 μM for H99, 6 μM for R265)^[1].
Urease-IN-24 (6-192 μM; 12 h) significantly increases plasma membrane permeability of Cryptococcus neoformans H99 and Cryptococcus gattii R265^[1].
Urease-IN-24 (0.06-1000 ng/mL; 10 min) potently inhibits Cryptococcus neoformans urease in a cell-free assay with a IC₅₀ of 89.96 nM and acts as a competitive inhibitor with a K_i of 64.3 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.